关注
Ronan Kelly
Ronan Kelly
Director of Oncology Baylor University Medical Center
在 BSWHealth.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer
RJ Kelly, JA Ajani, J Kuzdzal, T Zander, E Van Cutsem, G Piessen, ...
New England Journal of Medicine 384 (13), 1191-1203, 2021
11132021
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study
COVIDSurg Collaborative
Anaesthesia 76 (6), 748-758, 2021
555*2021
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
D Planchard, TM Kim, J Mazieres, E Quoix, G Riely, F Barlesi, PJ Souquet, ...
The Lancet Oncology 17 (5), 642-650, 2016
4822016
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
ED Thompson, M Zahurak, A Murphy, T Cornish, N Cuka, E Abdelfatah, ...
Gut 66 (5), 794-801, 2017
4492017
Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors
K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ...
Journal of Thoracic Oncology 13 (12), 1930-1939, 2018
3612018
Scientific advances in lung cancer 2015
AS Tsao, GV Scagliotti, PA Bunn Jr, DP Carbone, GW Warren, C Bai, ...
Journal of Thoracic Oncology 11 (5), 613-638, 2016
3412016
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial
A Lopez-Chavez, A Thomas, A Rajan, M Raffeld, B Morrow, R Kelly, ...
Journal of clinical oncology 33 (9), 1000-1007, 2015
2542015
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers
R Hassan, SJ Cohen, M Phillips, I Pastan, E Sharon, RJ Kelly, ...
Clinical cancer research 16 (24), 6132-6138, 2010
2382010
Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin
RJ Kelly, A Lopez-Chavez, D Citrin, JE Janik, JC Morris
Molecular cancer 10, 1-11, 2011
2202011
Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection
PA McCullough, RJ Kelly, G Ruocco, E Lerma, J Tumlin, KR Wheelan, ...
The American journal of medicine 134 (1), 16-22, 2021
2162021
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors
G Giaccone, A Rajan, A Berman, RJ Kelly, E Szabo, A Lopez-Chavez, ...
Journal of Clinical Oncology 29 (15), 2052-2059, 2011
2072011
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer
RJ Kelly, D Draper, CC Chen, RW Robey, WD Figg, RL Piekarz, X Chen, ...
Clinical Cancer Research 17 (3), 569-580, 2011
2062011
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors
A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, ...
Clinical cancer research 18 (8), 2344-2351, 2012
1902012
Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011
YCT Shih, F Smieliauskas, DM Geynisman, RJ Kelly, TJ Smith
Journal of Clinical Oncology 33 (19), 2190-2196, 2015
1842015
Thymic malignancies: from clinical management to targeted therapies
RJ Kelly, I Petrini, A Rajan, Y Wang, G Giaccone
Journal of clinical oncology 29 (36), 4820-4827, 2011
1702011
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
RJ Kelly, A Thomas, A Rajan, G Chun, A Lopez-Chavez, E Szabo, ...
Annals of oncology 24 (10), 2601-2606, 2013
1682013
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): A single-arm, phase 1b–2 trial
DVT Catenacci, YK Kang, H Park, HE Uronis, KW Lee, MCH Ng, ...
The lancet oncology 21 (8), 1066-1076, 2020
1662020
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas
A Rajan, RJ Kelly, JB Trepel, YS Kim, SV Alarcon, S Kummar, M Gutierrez, ...
Clinical Cancer Research 17 (21), 6831-6839, 2011
1472011
Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis
D Planchard, B Besse, HJM Groen, SMS Hashemi, J Mazieres, TM Kim, ...
Journal of Thoracic Oncology 17 (1), 103-115, 2022
1392022
Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy
K Suresh, KJ Psoter, KR Voong, B Shankar, PM Forde, DS Ettinger, ...
Journal of Thoracic Oncology 14 (3), 494-502, 2019
1362019
系统目前无法执行此操作,请稍后再试。
文章 1–20